TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02607007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2% M.F. Milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strawberry Jam

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strawberry Jam

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strawberry Jam

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strawberry Jam

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 31% M.F. Cheddar Cheese

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2% M.F. Plain Greek yogurt

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy Beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Study: NCT01675427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interleukin 28B testing
Description: Blood sampling for ILB28 genotyping
Study: NCT00438451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: LEV 250 mg capusles: week 1 and 2 0-0-1, week 3 and 4 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (500 - 3000 mg)during maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: CBZ 100 mg capusles: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (200 - 1200 mg) during maintenance depending on tolerance and efficacy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: LTG 25 mg encapsulated: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 caps. per day (50 - 300 mg)during maintenance depending on tolerance and efficacy.
Study: NCT03516487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1618
Description: SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1618
Description: SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.
Study: NCT01953861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC905
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC905
Description: Oral
Study: NCT03808077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0.3mg/kg/hr
Description: The Moderate NMB group (Control ) will have rocuronium infusion titrated to moderate paralysis defined as TOF of 1-2 (infusion start rate 0.005mg/kg/min or 0.3mg/kg/hr).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 1.5mg/kg/hr
Description: The Deep NMB group (Intervention) will have rocuronium infusion titrated to deep paralysis defined as PTC of 1-2 (infusion start rate 0.025mg/kg/min or 1.5mg/kg/hr).
Study: NCT00531479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voriconazole
Description: First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV BID plus anidulafungin placebo IV qd.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin placebo IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin placebo IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anidulafungin
Description: First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole
Description: First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.
Study: NCT03136276

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IPS Empress CAD
Description: standard etchable glass ceramics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polished Celtra Duo
Description: new glass ceramic material
Study: NCT03516487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1618
Description: SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.
Study: NCT01953861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC905
Description: Oral
Study: NCT01291654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: po Paracetamol 15 mg/kg every 6 hours x 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: IV indomethacin 2 mg/kg/dose for three doses at 12 hour intervals; or IV Ibuprofen 10 mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals (total of 3 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D5W
Description: Since the paracetamol is given q 6 hours, in order to maintain blinding of the clinical staff, a placebo (D5W) must be given intermittently between the doses of NSAID such that each infant will receive drug every 6 hours.
Study: NCT01240876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-37247
Description: 0.5-, 1-, 3-, 6-, and 12-mg doses of CEP-37247 will be administered by the transforaminal epidural route.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo vials will be filled with the buffered solution for CEP-37247.
Study: NCT03024814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: The first group will receive acetaminophen as the following~1. Loading dose: 20 mg/kg in the first 12-24 hours To be diluted in D5W up to 3-5 ml and to be infused over 15 minutes.~2. Maintenance dose: 7.5 mg/kg after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 5
Description: The second group will receive placebo (D5W) as the following~1. Loading dose: 3-5 ml in the first 12-24 hours To be infused over 15 minutes.~2. Maintenance dose: 3-5 ml after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days.
Study: NCT03516487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1618
Description: SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1618
Description: SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive placebo orally in a chilled buffered solution (100 mL).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive placebo orally in a chilled buffered solution (100 mL).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive placebo orally in a chilled buffered solution (100 mL).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive placebo orally in a chilled buffered solution (100 mL).
Study: NCT01863355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B0 group: bolus 0.6mcg/kg without background infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BL group: bolus 0.4mcg/kg with background infusion rate 0.2mcg/kg/hr
Study: NCT03870945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART2019.1 Dose level 1
Description: This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL/CLL/SLL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART2019.1 Dose level 2
Description: This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL.
Study: NCT01863355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BH group: bolus 0.2mcg/kg with background infusion rate 0.4mcg/kg/hr
Study: NCT03614130

Intervention type: DEVICE
Group type: OTHER
Intervention: LID011121 contact lens
Description: Investigational silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: LID011121 contact lens
Description: Investigational silicone hydrogel contact lens
Study: NCT00890279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilnidipine
Description: Cilnidipine up to 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imidapril
Description: Imidapril up to 10 mg per day
Study: NCT04042649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: environmental intervention
Description: provide environmental intervention (help sleep cycle, provide comfortable environment)
Study: NCT01438476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous Patient-Controlled Analgesia (IVPCA)
Description: Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures.
Study: NCT03614130

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lens
Description: Commercially available silicone hydrogel contact lens
Study: NCT02563600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-letter telephone call.
Description: A brief 2-10 min telephone call made to the patient prior to receipt of appointment invitation letter.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-letter telephone call
Description: A brief 2-10 min telephone call made to the patient after receipt of appointment invitation letter.
Study: NCT02790606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covera(TM) Vascular Covered Stent
Description: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.
Study: NCT02652130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remestemcel-L
Description: No intervention was given in Study MSB-GVHD002 (NCT02652130). It was a safety follow-up trial of remestemcel-L-treated participants from Study MSB-GVHD001.
Study: NCT01979978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Buddies Curriculum
Description: Each week, intermediate students will receive a 45-minute healthy-living lesson plan from their classroom teacher. Later that week, intermediate students will serve as peer mentors (Buddies), teaching a 30-minute lesson to their younger students. The Physical activity (i.e.Go Move!) component of the lesson plans includes 30-minutes of structured aerobic fitness sessions, called fitness loops, with the student pairs twice weekly. The dietary (Go Fuel!) component includes lessons about distinguishing nutritious and from unhealthy (nutrient poor-energy rich) foods and beverages. The body image (Go Feel Good!) component, the students are taught to value classmates based on individual traits rather than peer influence.
Study: NCT02222415

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exercise + Protein drink

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Exercise + Protein drink
Study: NCT03070392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMCgp100
Description: IMCgp100 is to be administered at 20 mcg cycle 1 day1, then 30 mcg cycle 1 day 8, then 68 mcg cycle 1 day 15 and weekly thereafter by IV infusion over 15 minutes until confirmed disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine is to be administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab is to be administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab is to be administered at 2 mg/kg IV infusion up to a maximum of 200 mg administered Intravenously over 30 minutes every 3 weeks or 200 mg fixed dose administered intravenously every 3 weeks where approved locally until confirmed disease progression or unacceptable toxicity
Study: NCT00121940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Care
Description: Specially trained registered nurse (Guided Care Nurse) based in a primary care practice collaborates with two primary care physicians to provide seven services for 40-60 high-risk patients: comprehensive assessment and care planning; best practices for chronic conditions; self-management; healthy lifestyles; coordinating care; educating and supporting unpaid caregivers; and accessing community resources.
Study: NCT00274989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: First-Line Therapy: Bendamustine i.v. 90 mg/m² day 1-2, q4wks, cycle 1 to 6~2nd to 4th -Line Therapy: Bendamustine i.v. 70 mg/m² day 1-2 q4wks, cycle 1 to 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: First-Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6~2nd to 4th -Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6
Study: NCT01071694

Intervention type: DRUG
Intervention: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)
Description: Patients receiving Betaferon according to routine clinical practice
Study: NCT03783455

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non arthroscopic joint lavage
Description: Instillation of 4 litters of cold physiological serum

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non arthroscopic joint lavage plus corticosteroid
Description: Instillation of 4 litters of cold physiological serum followed by intraarticular injection of triamcinolone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non arthroscopic joint lavage plus hyaluronic acid
Description: Instillation of 4 litters of cold physiological serum followed by intraarticular injection of hyaluronic acid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular injection of corticosteroid
Description: Intraarticular injection containing 40 mg of triamcinolone acetonide.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular injection of hyaluronic acid
Description: Intraarticular injection containing 4 mL of a bioengineered hyaluronic acid.
Study: NCT04488250

Intervention type: OTHER
Group type: OTHER
Intervention: Robot Therapy
Description: Robot Therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Robot Therapy
Description: Robot Therapy
Study: NCT00826280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regadenoson
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regadenoson
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: regadenoson
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: overencapsulated caffeine
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: overencapsulated caffeine
Description: oral

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: technetium
Description: IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: technetium
Description: IV

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: technetium
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study: NCT01438476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia (TEA)
Description: Thoracic epidurals (needle inserted into the space between the covering of spinal cord and the cord itself) placed preoperatively in either the holding area or in the operating room.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Assessment
Description: Hourly post surgery rating level of pain on a scale of 0-10.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Assessment
Description: Hourly post surgery rating level of pain on a scale of 0-10.
Study: NCT02673086

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: coracoid approach
Description: Coracoid approach for ultrasound guided infraclavicular brachial plexus block

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: retroclavicular approach
Description: retroclavicular approach for ultrasound guided infraclavicular brachial plexus block
Study: NCT02914886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apidra
Description: Half of patients with lipoatrophy will be switched randomly to insulin Apidra for 12 months. Any site other than the lipoatrophic site would be used for delivering the insulin for the purpose of this study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: current insulin
Description: Half of patients with lipoatrophy will still use their current Insulin for 6 months. After 6 months the current insulin will be switched to insulin Apidra for the next 6 months.
Study: NCT02556203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 10mg OD (once-daily)
Study: NCT03504124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Description: An 18-month multicomponent intervention, which includes protocol-based treatment using: a standard blood pressure (BP) management algorithm, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.
Study: NCT04099680

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial thickness recipient bed
Description: Flap will be separated by sharp dissection and elevated toward apical direction, leaving the periosteum covering the bone, and the elevated pedicle flap will be incised and removed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full thickness recipient bed
Description: Full-thickness (mucoperiosteal) flap will be raised on the recipient bed to establish a denuded bone area. Two bone screws will be placed at the most apical border of the denuded bone.
Study: NCT02556203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid (ASA)
Description: 75-100mg OD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (ASA)
Description: 75-100mg OD
Study: NCT04099680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone screw (FDA approved bone screw)
Description: Two bone screws placed at the most apical border of the denuded bone after osteotomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periosteal sutures
Description: Interrupted periosteal sutures placed at the 4 corners of each graft, and mesial and distal surfaces to engage the graft at an equidistance from the graft corners.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periosteal sutures
Description: Interrupted periosteal sutures placed at the 4 corners of each graft, and mesial and distal surfaces to engage the graft at an equidistance from the graft corners.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sling sutures
Description: Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and the periosteum apically.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sling sutures around screws
Description: Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and each is apically looped around the corresponding apically positioned screw.
Study: NCT01466374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline, Intravenous (IV), 0 mg, Once a week for the first week and every other week thereafter, 11 weeks
Study: NCT02360345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONX-0801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONX-0801
Study: NCT01466374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline, Intravenous, 0 mg, Every other week, Up to 337days
Study: NCT03387917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLD-1
Description: TLD-1 is a new liposomal formulation of the anthracycline doxorubicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caelyx
Description: Caelyx is a liposomal formulation of the anthracycline doxorubicin
Study: NCT04411940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol Tablets, Mylan Pharmaceuticals Inc.
Description: single dose, 2 mg Haloperidol tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol Tablets, Cycle Pharmaceuticals Ltd
Description: single dose, 2 mg Haloperidol tablet
Study: NCT00803855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: oral, single dose